{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:49:24Z","timestamp":1777492164166,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2022 High-Level Talent Research Project of Yunnan Provincial Health Commission","award":["2023-KHRCBZ-A02"],"award-info":[{"award-number":["2023-KHRCBZ-A02"]}]},{"name":"Open Projects for Construction Unit of Clinical Pharmacy Center of Yunnan Province","award":["2023YJZX-YX11"],"award-info":[{"award-number":["2023YJZX-YX11"]}]},{"name":"Open Projects for Construction Unit of Clinical Pharmacy Center of Yunnan Province","award":["2023YJZX-YX15"],"award-info":[{"award-number":["2023YJZX-YX15"]}]},{"name":"Open Projects for Construction Unit of Clinical Pharmacy Center of Yunnan Province","award":["2023YJZX-YX24"],"award-info":[{"award-number":["2023YJZX-YX24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00467-1","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T04:16:26Z","timestamp":1739852186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis"],"prefix":"10.1186","volume":"9","author":[{"given":"Qi","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"12","key":"467_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Comp\u00e1n","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511\u201321. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221035.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"467_CR2","doi-asserted-by":"publisher","first-page":"e000053","DOI":"10.1136\/rmdopen-2015-000053","volume":"1","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1(Suppl 1):e000053. https:\/\/doi.org\/10.1136\/rmdopen-2015-000053.","journal-title":"RMD Open"},{"issue":"6","key":"467_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383. https:\/\/doi.org\/10.1136\/ard.2009.108233.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"467_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","volume":"68","author":"C Stolwijk","year":"2016","unstructured":"Stolwijk C, van Onna M, Boonen A, van Tubergen A. Global prevalence of Spondyloarthritis: a systematic review and Meta-regression analysis. Arthritis Care Res (Hoboken). 2016;68(9):1320\u201331. https:\/\/doi.org\/10.1002\/acr.22831.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"467_CR5","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"467_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of Ankylosing spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285\u201399. https:\/\/doi.org\/10.1002\/acr.24025.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"467_CR7","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F Conti","year":"2007","unstructured":"Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66(10):1393\u20137. https:\/\/doi.org\/10.1136\/ard.2007.073569.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"467_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of Ixekizumab in the treatment of Radiographic Axial Spondyloarthritis: sixteen-week results from a phase III randomized, Double-Blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of Tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611. https:\/\/doi.org\/10.1002\/art.40753.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"467_CR9","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219601.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"467_CR10","doi-asserted-by":"publisher","first-page":"e002253","DOI":"10.1136\/rmdopen-2022-002253","volume":"8","author":"V Navarro-Comp\u00e1n","year":"2022","unstructured":"Navarro-Comp\u00e1n V, Wei JC, Van den Bosch F, Magrey M, Wang L, Fleishaker D, et al. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022;8(2):e002253. https:\/\/doi.org\/10.1136\/rmdopen-2022-002253.","journal-title":"RMD Open"},{"issue":"1","key":"467_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"467_CR12","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/jdv.19391","volume":"37","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Silverberg JI, Tha\u00e7i D, Papp KA, St\u00e4nder S, Beck LA, et al. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023;37(12):2558\u201368. https:\/\/doi.org\/10.1111\/jdv.19391.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"467_CR13","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D\u2019Haens G, et al. Efficacy and safety of Upadacitinib in a Randomized Trial of patients with Crohn\u2019s Disease. Gastroenterology. 2020;158(8):2123\u2013e21388. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.047.","journal-title":"Gastroenterology"},{"issue":"3","key":"467_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.025.","journal-title":"J Allergy Clin Immunol"},{"issue":"10341","key":"467_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5.","journal-title":"Lancet"},{"issue":"11","key":"467_CR16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022;81(11):1515\u201323. https:\/\/doi.org\/10.1136\/ard-2022-222608.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"467_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"issue":"3","key":"467_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s40744-023-00536-2","volume":"10","author":"V Navarro-Comp\u00e1n","year":"2023","unstructured":"Navarro-Comp\u00e1n V, Baraliakos X, Magrey M, \u00d6st\u00f6r A, Saffore CD, Mittal M, et al. Effect of Upadacitinib on Disease Activity, Pain, fatigue, function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis. Rheumatol Ther. 2023;10(3):679\u201391. https:\/\/doi.org\/10.1007\/s40744-023-00536-2.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"467_CR19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40744-023-00550-4","volume":"10","author":"U Kiltz","year":"2023","unstructured":"Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, et al. Effect of Upadacitinib on Quality of Life and Work Productivity in active non-radiographic Axial spondyloarthritis: results from Randomized Phase 3 Trial SELECT-AXIS 2. Rheumatol Ther. 2023;10(4):887\u201399. https:\/\/doi.org\/10.1007\/s40744-023-00550-4.","journal-title":"Rheumatol Ther"},{"issue":"10349","key":"467_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10349):369\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(22)01212-0.","journal-title":"Lancet"},{"issue":"1","key":"467_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/art","volume":"74","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, van der Heijde D, Sieper J, Van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Ostor A, Combe B, Sui Y, Chu AD, Song IH. Safety and Efficacy of Upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a Double-Blind, placebo-controlled study and open-label extension. Arthritis Rheumatol. 2022;74(1):70\u201380. 10.1002 \/art.","journal-title":"Arthritis Rheumatol"},{"issue":"10214","key":"467_CR22","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019;394(10214):2108\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(19)32534-6.","journal-title":"Lancet"},{"key":"467_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23. https:\/\/doi.org\/10.1186\/s41927-018-0031-x.","journal-title":"BMC Rheumatol"},{"issue":"9","key":"467_CR24","doi-asserted-by":"publisher","first-page":"CD006829","DOI":"10.1002\/14651858.CD006829.pub2","volume":"2012","author":"LJ Nannini","year":"2012","unstructured":"Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;2012(9):CD006829. https:\/\/doi.org\/10.1002\/14651858.CD006829.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"467_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","volume":"49","author":"PA Lord","year":"2010","unstructured":"Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL, et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49(3):563\u201370. 10.1093 \/rheumatology\/kep422.","journal-title":"Rheumatology (Oxford)"},{"issue":"21","key":"467_CR26","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, Peyrin-Biroulet L, D\u2019Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388(21):1966\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2212728.","journal-title":"N Engl J Med"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00467-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T04:16:32Z","timestamp":1739852192000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00467-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00467-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4760609\/v1","asserted-by":"object"}]},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}